US 12,188,949 B2
Noninvasive method to quantify kidney function and functional decline
Minnie M. Sarwal, San Francisco, CA (US); and Joshua Y. Yang, San Francisco, CA (US)
Assigned to The Regents of The University of Califomia, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Aug. 1, 2022, as Appl. No. 17/878,736.
Application 17/878,736 is a continuation of application No. 17/387,917, filed on Jul. 28, 2021, granted, now 11,435,366.
Application 17/387,917 is a continuation of application No. PCT/US2020/049387, filed on Sep. 4, 2020.
Claims priority of provisional application 62/896,296, filed on Sep. 5, 2019.
Prior Publication US 2023/0072969 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/351 (2006.01); A61P 13/12 (2006.01); G01N 33/68 (2006.01); G01N 33/70 (2006.01)
CPC G01N 33/6893 (2013.01) [A61P 13/12 (2018.01); G01N 33/70 (2013.01); G01N 2800/347 (2013.01)] 27 Claims
 
1. A method for determining kidney function of a subject from a urine sample, the method comprising:
detecting an amount of asymmetric dimethylarginine (ADMA) from a urine sample of a subject;
assaying the urine sample to determine a hydration status of the subject; and
generating a value indicative of the kidney function of the subject based on the amount of ADMA from the urine sample and the hydration status of the subject;
determining the kidney function of the subject based on the value.